Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration

Stopped early · Phase 4 · Has a placebo group

Conditions studied: Platelet Aggregation

In brief

Aspirin has shown to be beneficial to some patients with certain diseases such as coronary artery disease or stroke. We are investigating how aspirin works on regulating platelets and thromboxane over time at different doses. We hope to find the best dose of aspirin and/or other medications to help people who are at risk for heart attack or stroke.

Key facts

Study ID

NCT00748371

Run by

Vanderbilt University

People needed

51

Starts

2004-06-01

Expected to finish

2011-02-01

Last updated by the study team

2017-04-12

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Males
• Age 18-40 years
• Non-smokers

You may not qualify if…

• ASA/NSAID use previous 14 days.
• Evidence of ASA/NSAID use within previous 14 days at baseline visit based on investigator interpretation of platelet aggregation and platelet secretion studies.
• History of chronic NSAID use.
• Currently taking NSAIDs, corticosteroids, or anticoagulants.
• History of coronary artery disease, myocardial infarction, coronary artery bypass grafting, percutaneous angioplasty, diabetes mellitus or stroke.
• History of gastric,duodenal, or esophageal ulcers or serious gastrointestinal bleed.
• History of frequent headaches, pain syndrome, or other condition requiring frequent use of analgesics.
• History of adverse reaction to ASA.
• Initial platelet count <100K/µl or >500K/µl.
• Initial hematocrit <35% or >50%.
• Weight less than 110 pounds.

Where it is running

• Vanderbilt University — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.